Bi CNU
Bi CNU Brand names, Bi CNU Analogs
Bi CNU Brand Names Mixture
- No information avaliable
Bi CNU Chemical_Formula
C5H9Cl2N3O2
Bi CNU RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Bi CNU fda sheet
Bi CNU msds (material safety sheet)
Bi CNU Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Bi CNU Molecular Weight
214.049 g/mol
Bi CNU Melting Point
31 oC
Bi CNU H2O Solubility
< 0.1 g/100 mL at 18 °C
Bi CNU State
Solid
Bi CNU LogP
1.256
Bi CNU Dosage Forms
Powder for solution; Wafer
Bi CNU Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Bi CNU Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Bi CNU Absorption
5 to 28% bioavailability
Bi CNU side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Bi CNU Patient Information
No information avaliable
Bi CNU Organisms Affected
Humans and other mammals
